Levocetirizine (Allerway, Allerway Meltaway)
Levocetirizine
Dr Reddyæs Laboratories (Pty) Ltd
Registration
- Applicant
- Dr Reddyæs Laboratories (Pty) Ltd
- Certificate holder
- Dr. Reddy’s Laboratories (Pty) Ltd.
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Allerway 5 EACH TABLET CONTAINS LEVOCETIRIZINE DIHYDROCHLORIDE 5,0 mg | 5 mgFilm-coated tablet | 43081543/5.7.1/0815Approved 17 July 2024 | Registered | Not determined | PIPIL |
| Allerway meltaway 5 EACH TABLET CONTAINS LEVOCETIRIZINE DIHYDROCHLORIDE 0,5 mg | 5 mgTablet | 55071255/5.7.1/0712Approved 23 May 2023 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S1: Levocetirizine
Consolidated Schedules 06 July 2026, line 775
3 of 9 approved products with this ingredient carry S2 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.